Dr. Yongping Wang is the director for the Cell and Gene Therapy Lab (CGTL) at the Children’s Hospital of Philadelphia (CHOP), and an associate professor of Clinical Pathology and Laboratory Medicine at the University of Pennsylvania (UPenn) Perelman School of Medicine. He has been at CGTL for 11 years. CGTL is a current Good Manufacturing Practice (cGMP) facility accredited by the Foundation for the Accreditation of Cellular Therapy (FACT) and the College of American Pathologists (CAP). It processes and manufactures cell and gene therapy (CGT) products for bone marrow transplant and other CGT patients at CHOP. These range from standard-of-care, to investigational (IND/IDE), to commercially available CGT products. CGTL is currently involved in more than 50 trials that cover transplant graft manipulation, virus specific T cells, Chimeric Antigen T (CAR-T) cells, and gene therapy for hemoglobinopathies. Sponsors for these trials include internal CHOP investigators, outside academic institutions, and industrial/commercial collaborators. With its partners at UPenn, CHOP was the main clinical site that conducted the trials that lead to the FDA approval of Kymriah. By the end of 2022, CHOP has infused more than 400 unique CAR-T patients.
Dr. Wang obtained his Bachelor of Science degree from Yale University, and his MD, PhD at Dartmouth Medical School. He did his Clinical Pathology residency and Transfusion Medicine fellowship at the Hospital of the University of Pennsylvania.
